Consensus AnaptysBio, Inc.

Equities

ANAB

US0327241065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
21.47 ^USD	+0.61%		-3.16%	+0.23%

Apr. 16	Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	MT
Apr. 11	Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	MT

Evolution of the average Target Price on AnaptysBio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9bc878257fe0d85cd4cecad27ab37.nBkV4gPJ11OCVXlhC8fnAw0awjzHirF65qejZCP-ZTA.6V1YtmGc5R_aBjIpaIK9endpl3WRzOUUk-_hVlTNM0X-cEqxS_2jYOggLA~dcd8aa51a60c107ebb8c4ebf13d04cb6

Analyst Recommendations on AnaptysBio, Inc.

Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	Apr. 16	MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	Apr. 11	MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating	Apr. 01	MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20	Mar. 12	MT
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target	Feb. 26	MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	Feb. 16	MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target	Feb. 16	MT
Wedbush Lifts AnaptysBio's PT to $20 From $18 Due to Updated Cash Guidance, Keeps Neutral Rating	Nov. 03	MT
UBS Cuts AnaptysBio Price Target to $21 From $28, Maintains Neutral Rating	Nov. 01	MT
Wedbush Lowers AnaptysBio's PT to $18 From $26, Adjusts Launch Estimates, Addition of Ulcerative Colitis for Rosnilimab; Keeps Neutral Rating	23-10-26	MT
Wedbush Lowers AnaptysBio's Price Target to $26 From $29, Keeps Neutral Rating	23-08-08	MT
JPMorgan Upgrades AnaptysBio to Neutral From Underweight, Trims Price Target to $30 From $31	23-05-22	MT
Guggenheim Adjusts AnaptysBio Price Target to $45 From $44, Maintains Buy Rating	23-05-12	MT
JPMorgan Adjusts Price Target on AnaptysBio to $31 From $32, Keeps Underweight Rating	23-04-12	MT
Raymond James Downgrades AnaptysBio to Market Perform From Outperform	23-01-06	MT
Wedbush Lowers AnaptysBio's PT to $29 From $32, Removes Valuations for Rosnilimab in Rheumatoid Arthritis, ANB032 in Atopic Dermatitis; Keeps Neutral Rating	23-01-06	MT
JPMorgan Adjusts Price Target on AnaptysBio to $32 From $24, Maintains Underweight Rating	22-11-18	MT
Raymond James Raises Price Target on AnaptysBio to $38 From $30, Maintains Outperform Rating	22-11-09	MT
Wedbush Raises AnaptysBio's PT to $32 From $21, Changes Launch Estimate for Rosnilimab in Alopecia, Adjusts Cost of Capital; Keeps Neutral Rating	22-11-09	MT
Guggenheim Upgrades AnaptysBio to Buy Rating From Neutral	22-11-01	MT
HC Wainwright Assumes AnaptysBio at Buy with $35 Price Target	22-09-19	MT
Truist Securities Downgrades AnaptysBio to Hold From Buy, Cuts Price Target to $28 From $50	22-09-13	MT
Wedbush Adjusts AnaptysBio Price Target to $21 From $24, Maintains Neutral Rating	22-09-12	MT
Wedbush Cuts Price Target on AnaptysBio to $24 From $33 on Imsidolimab Update, Maintains Neutral Rating	22-09-01	MT
Raymond James Starts AnaptysBio at Outperform With $35 Price Target	22-09-01	MT